Agenus Inc.

NASDAQ:AGEN

Biotechnology

Healthcare
$6.40 -0.17%

-$0.01 today

Market cap
$289.58M
Beta
1.54
P/E (TTM)
1.7
EPS (TTM)
$1.70
52W Low $2.71High $7.34

Volume 0.88M

Average 0.82M

AGEN Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Agenus Inc.NASDAQ: AGEN

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents rises 89.3% from a year ago

Cash & equivalents stood at $35M at the end of Q1 FY2026, up 89.3% from a year earlier and up 1067.3% from the prior quarter. Over 3 fiscal years it compounded at -74.4% a year.

Context

  • Cash & equivalents amounted to 18.8% of total assets at the end of Q1 FY2026, up 9.5 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +89.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35M+1067.3% QoQ
Last fiscal yearDec 2025
$3M-92.6% YoY
Year agoMar 2025
$18.49M+89.3% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+89.3%——
1 year-92.6%——
3-year CAGR-74.4%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
3M USD
Year-over-year change
-92.6%
4-year CAGR
-68.2%

Cash & Equivalents vs competitors

How AGEN compares with its peers on the latest reported figures

  • AGEN's Mar 2026 cash & equivalents of $35M is the 5th highest of the 10 companies compared; the peer median is $31.93M.
  • Its year-over-year change of +89.3% is the highest of 9, against a peer median of -10.8%.
  • Cash & equivalents amounts to 18.8% of total assets for AGEN, versus a peer median of 21.2%.
AGEN Competitors Peer median
Cash & Equivalents for AGEN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IRDOpus Genetics, Inc.Mar 2026$59.96M +43.5%+1.9%89.8%
ABOSAcumen Pharmaceuticals, Inc.Mar 2026$51.8M +71.7%-25.4%38.8%
SEERSeer, Inc.Mar 2026$47.32M -9.8%-3.9%17.4%
FATEFate Therapeutics, Inc.Mar 2026$39.57M -11.9%-8.7%13.9%
AGENAgenus Inc.Mar 2026$35M +89.3%-74.4%18.8%
ZNTLZentalis Pharmaceuticals, Inc.Mar 2026$31.93M -23.8%-5.8%12.6%
INOInovio Pharmaceuticals, Inc.Mar 2026$26.27M -34.2%-1.5%52.8%
PLRXPliant Therapeutics, Inc.Mar 2026$22.19M -75.9%+10.5%11.0%
TTRXTurn Therapeutics Inc.Mar 2026$11.22M ——60.2%
HURATuHURA Biosciences, Inc.Mar 2026$6.3M +1.3%-36.7%21.2%
Peer median (excluding AGEN) $31.93M-10.8%-4.8%21.2%

Competitors are the stored peer set for AGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents291.93M178.67M76.11M40.44M3M
Short-term Investments14.99M14.68M000
Net Receivables1.52M2.74M25.84M407K1.83M
Inventory20.36M13.83M000
Other Current Assets(17.19M)(10.64M)2.37M2.42M128.61M
Total Current Assets331.97M213.12M112.42M45.57M133.44M
Property, Plant & Equipment (Net)91.08M164.29M163.03M147.4M24.25M
Goodwill24.88M25.47M24.72M24.09M24.09M
Intangible Assets8.49M6.23M4.41M3.38M3.04M
Long-term Investments003.22M4.64M42.73M
Tax Assets(2.67M)(2.67M)000
Other Non-current Assets12.21M7.12M6.11M1.19M(742K)
Total Non-current Assets133.98M200.43M201.5M180.7M93.36M
Total Assets465.96M413.56M313.91M226.27M226.8M
Account Payables30.49M40.94M61.45M61.47M82.99M
Short-term Debt728K575K146K2.7M155.11M
Tax Payables00000
Deferred Revenue12.43M12.27M18K31K1.14M
Other Current Liabilities75.66M101.49M141.21M121.85M83.11M
Total Current Liabilities156.94M188.95M255.9M221.4M323.49M
Long-term Debt12.82M12.58M12.77M30.47M169.66M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)11.2M1.14M1.14M1.14M1.14M
Other Non-current Liabilities194.97M202.45M125.26M225.13M242K
Total Non-current Liabilities261.11M279.51M206.4M311.29M181.17M
Total Liabilities418.05M468.46M462.3M532.7M504.66M
Common Stock2.57M3.06M3.94M236K353K
Retained Earnings(1.49B)(1.71B)(1.96B)(2.18B)(2.18B)
Accumulated OCI1.49M915K(955K)(1.4M)(439K)
Other Stockholders Equity00000
Minority Interest13.47M6.38M11.95M19.96M(6.75M)
Total Equity47.91M(54.9M)(148.38M)(306.42M)(277.86M)
Total Debt58.29M78.43M93.19M94.87M334.9M
Net Debt(233.64M)(100.25M)17.08M54.43M331.9M

Agenus Inc.

NASDAQ:AGEN

Intrinsic Alpha fair value

Locked

Current Price

$6.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.